10 Stocks Insiders Are Selling In March

1. Blueprint Medicines Corporation (NASDAQ:BPMC)

Number of Insiders Selling: 11

Market Capitalization: $5.73 billion

First among the 10 stocks insiders are selling this month is the biopharmaceutical company Blueprint Medicines. The Cambridge, Massachusetts-headquartered company is focused on developing targeted treatments for cancers and blood disorders. Its main revenue stream is AYVAKIT (avapritinib), a treatment for systemic mastocytosis (SM) and gastrointestinal stromal tumors.

Additionally, Blueprint Medicines is working on BLU-263, a potent, orally available KIT inhibitor designed to treat indolent SM and other mast cell disorders. The company is also developing GAVRETO for patients with RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma.

For the full year of 2024, the company reported revenues of $508.8 million, including $479.0 million in net product revenues from sales of AYVAKIT and $29.9 million in collaboration and license revenues. Blueprint Medicines recorded $72.0 million and $249.4 million in revenues in the fourth quarter and year ended Dec. 21, 2023, respectively. Net loss for the year 2024 was $67.1 million, compared to a net loss of $507.0 million in 2023. As of Dec. 31, 2024, cash, cash equivalents and investments were $863.9 million, as compared to $767.2 million as of Dec. 31, 2023.

The company projects 2025 revenue of $680 million to $710 million suggesting AYVAKIT is on track to achieve $2 billion in revenue by 2030.

In March, 11 insiders, including the company’s CEO, CSO, and CFO, sold a total of around $6.69 million worth of Blueprint Medicines shares at an average price of $89.50 per share. Currently, the stock trades at $89.58 per share, having gained 2.71% year-to-date, and 3.18% over the past 12 months.

According to StockAnalysis, the consensus rating for Blueprint Medicines stock from 20 analysts is “Buy.” The average price target is $125.0, suggesting an upside of 39.54%.

Blueprint Medicines is also among the 10 oversold biotech stocks to buy now.

Overall, BPMC ranks first among the 10 stocks insiders are selling in March. While we acknowledge the potential of BPMC, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BPMC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.